METHODS	In this open-label , parallel-group , multicenter , noninferiority registration study , patients were randomized ( 1:1 ) to add exenatide QW ( 2 mg ) or once-daily insulin glargine ( starting dose , 4 U ) to their current oral antidiabetes drug treatment .\